198 related articles for article (PubMed ID: 23454247)
21. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
22. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
[TBL] [Abstract][Full Text] [Related]
23.
Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
Molecules; 2020 May; 25(10):. PubMed ID: 32429033
[TBL] [Abstract][Full Text] [Related]
24. Cyclic versus Noncyclic Chelating Scaffold for
Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082
[TBL] [Abstract][Full Text] [Related]
25. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
[TBL] [Abstract][Full Text] [Related]
26. Advancing
Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
[TBL] [Abstract][Full Text] [Related]
27. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.
Oude Munnink TH; Arjaans ME; Timmer-Bosscha H; Schröder CP; Hesselink JW; Vedelaar SR; Walenkamp AM; Reiss M; Gregory RC; Lub-de Hooge MN; de Vries EG
J Nucl Med; 2011 Dec; 52(12):2001-8. PubMed ID: 22072706
[TBL] [Abstract][Full Text] [Related]
28. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
29. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
30. Development of [
Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372
[TBL] [Abstract][Full Text] [Related]
31. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L
Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347
[TBL] [Abstract][Full Text] [Related]
32. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
33. Preparation of clinical-grade (89) Zr-panitumumab as a positron emission tomography biomarker for evaluating epidermal growth factor receptor-targeted therapy.
Wei L; Shi J; Afari G; Bhattacharyya S
J Labelled Comp Radiopharm; 2014 Jan; 57(1):25-35. PubMed ID: 24448743
[TBL] [Abstract][Full Text] [Related]
34. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
35. Evaluation and selection of a lead diabody for interferon-γ PET imaging.
Rezazadeh F; Ramos N; Saliganan AD; Barr S; Peraino N; Schomburg F; Rancour D; Viola NT
Nucl Med Biol; 2022; 114-115():162-167. PubMed ID: 35753939
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of [
Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
[TBL] [Abstract][Full Text] [Related]
37. A Systematic Evaluation of Antibody Modification and
Sharma SK; Glaser JM; Edwards KJ; Khozeimeh Sarbisheh E; Salih AK; Lewis JS; Price EW
Bioconjug Chem; 2021 Jul; 32(7):1177-1191. PubMed ID: 32197571
[TBL] [Abstract][Full Text] [Related]
38. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
[TBL] [Abstract][Full Text] [Related]
39. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
[TBL] [Abstract][Full Text] [Related]
40. PET/CT Imaging of Human TNFα Using [
Beckford-Vera DR; Gonzalez-Junca A; Janneck JS; Huynh TL; Blecha JE; Seo Y; Li X; VanBrocklin HF; Franc BL
Mol Imaging Biol; 2020 Feb; 22(1):105-114. PubMed ID: 31065895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
